3D printed drugs market seen reaching $0.81 billion by 2030

The Business Research Company says the 3D printed drugs market is on track to grow from $0.36 billion in 2025 to $0.81 billion by 2030 as personalized medicine, AI-assisted formulation and on-demand manufacturing gain traction. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - 3D printed drugs could change how medicines are tailored, made and delivered, with more precise dosing and customized release profiles. - The market’s projected growth signals rising demand for personalized medicine across chronic disease care, oncology and neurology. - The shift also points to broader adoption of digital pharmaceutical manufacturing in healthcare settings.

What happened: - The Business Research Company projected the global three-dimensional (3D) printed drugs market will rise from $0.36 billion in 2025 to $0.42 billion in 2026. - The firm forecast the market will reach $0.81 billion by 2030. - The company estimated a 17.4% CAGR from 2025 to 2026 and a 17.6% CAGR from 2026 to 2030.

The details: - 3D printed drugs are made with additive manufacturing, building dosage forms layer by layer from digital blueprints. - The process allows control over composition, release characteristics and complex structural designs that are difficult to produce with traditional methods. - The technology supports personalized medications and novel dosage forms aimed at better efficacy, safety and patient compliance. - Growth drivers include demand for tailor-made medicine, advances in additive manufacturing, more chronic disease cases, expanded pharmaceutical R&D and a stronger focus on dosage precision. - Looking ahead, The Business Research Company pointed to digital pharmaceutical manufacturing platforms, AI-assisted drug formulation, on-demand drug production, precision medicine in oncology and neurology, and multi-material pharmaceutical printing. - The report cited growing use of personalized dosage forms, complex multi-drug release structures, layer-by-layer fabrication, rapid prototyping of customized oral dosage forms and low-volume pharmaceutical manufacturing. - The company said the market is expanding because personalized medicine customizes treatments using patient details such as genetic makeup, age, disease status and therapeutic response. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, more than double the number in 2022. - The report covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.

Between the lines: - The forecast suggests 3D printing is moving from a niche manufacturing concept toward a practical tool for targeted drug production. - North America’s lead reflects established healthcare infrastructure and a strong pharmaceutical base. - Asia-Pacific’s faster expected growth points to rising investment and expanding manufacturing capacity in the region. - The market report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

What's next: - Wider adoption will likely depend on regulatory acceptance, manufacturing scale-up and continued investment in digital production tools. - Personalized therapies and on-demand medicine production are expected to remain the main commercial use cases. - The market may see more activity in precision oncology, neurology and low-volume specialty drugs.

The bottom line: - The 3D printed drugs market is still small, but rapid growth forecasts show it is becoming a meaningful part of the pharmaceutical manufacturing shift.